FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2538625641> ?p ?o ?g. }

• W2538625641 abstract "Abstract Background Several observational studies in patients at high risk of arterial vascular disease have shown that statin use is associated with a decreased risk of venous thromboembolism (VTE). A recent meta-analysis showed that the odds ratio for a first venous thromboembolic event for statin users was 0.89 (95% confidence interval [CI], 0.78–1.01) compared with non-users (Rahmini K, et al. PLoS Med 2012;9: e1001310 doi:10.1371/journal.pmed.1001310). Objective To evaluate the risk of recurrent VTE in patients with VTE treated with an anticoagulant (rivaroxaban or enoxaparin/vitamin K antagonist [VKA]) in relation to the concomitant use of statin therapy in the EINSTEIN-DVT and EINSTEIN-PE studies. Measurements Incidence densities of symptomatic recurrent VTE and major bleeding were expressed per 100 patient-years of exposure (or not) to statins. A Cox proportional hazards model was employed, with statin use as a time-dependent variable, for each treatment group (rivaroxaban vs enoxaparin/VKA) and adjusted for aspirin use, age, body mass index, cardiac disorders, gender, and creatinine clearance at baseline. Results A total of 1509 (18%) of the 8240 patients included in EINSTEIN-DVT and EINSTEIN-PE used statins during the course of the studies. Statin users were more likely to have cardiovascular disorders (31% vs 10%) and also used aspirin more often (26% vs 5%). During statin/rivaroxaban treatment, recurrent VTE occurred with an incidence of 2.0 per 100 patient-years versus 3.6 during non-statin-use (adjusted hazard ratio [HR], 0.62; 95% CI, 0.29–1.32). During statin/enoxaparin/VKA use, recurrent VTE occurred at an incidence of 3.2 per 100 patient-years versus 4.0 during non-statin-use (adjusted HR, 0.89; 95% CI, 0.47–1.69). Major bleeding during statin/rivaroxaban treatment occurred at an incidence of 2.2 per 100 patient-years versus 1.6 during non-statin-use (adjusted HR, 0.92; 95% CI, 0.43–1.98). During statin/enoxaparin/VKA treatment, the rate of major bleeding was 3.7 per 100 patient-years compared with 3.0 during non-statin-use (adjusted HR, 0.69; 95% CI, 0.36–1.32). Due to the adjustments in the Cox regression model the direction of these hazard ratios are in contrast to the crude comparison of rates by patient-years. This is largely because, in general, statin users are older and most of the major bleeding events in statin users occur in the ≥60 years age group. Limitations The study comprised a post-hoc analysis of data collected in two randomized clinical trials. Because the analyses were not a comparison of randomized groups, residual confounding is possible. Conclusions A modest, but not statistically significant, reduction in recurrent VTE was observed with statin use in patients treated for VTE. This reduction was similar in patients receiving enoxaparin/VKA or rivaroxaban therapy. Disclosures: Gebel: Bayer HealthCare AG: Employment, Equity Ownership. Prins:Bayer HealthCare: Consultancy, Honoraria, Research Funding; Boehringer Ingelheim: Consultancy, Honoraria, Research Funding; sanofi-aventis: Consultancy, Honoraria, Research Funding; GlaxoSmithKline: Consultancy, Honoraria, Research Funding; Daiichi Sankyo: Consultancy, Honoraria, Research Funding; LeoPharma: Consultancy, Honoraria, Research Funding; ThromboGenics: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria, Research Funding. Lensing:Bayer HealthCare: Employment." @default.
• W2538625641 created "2016-10-28" @default.
• W2538625641 creator A5065301587 @default.
• W2538625641 creator A5081944182 @default.
• W2538625641 creator A5084922482 @default.
• W2538625641 date "2013-11-15" @default.
• W2538625641 modified "2023-09-29" @default.
• W2538625641 title "Statin Use Was Associated With a Non-Significant Reduction In The Observed Incidence Of Recurrent VTE In Einstein-DVT and Einstein-PE" @default.
• W2538625641 doi "https://doi.org/10.1182/blood.v122.21.1135.1135" @default.
• W2538625641 hasPublicationYear "2013" @default.
• W2538625641 type Work @default.
• W2538625641 sameAs 2538625641 @default.
• W2538625641 citedByCount "0" @default.
• W2538625641 crossrefType "journal-article" @default.
• W2538625641 hasAuthorship W2538625641A5065301587 @default.
• W2538625641 hasAuthorship W2538625641A5081944182 @default.
• W2538625641 hasAuthorship W2538625641A5084922482 @default.
• W2538625641 hasConcept C120665830 @default.
• W2538625641 hasConcept C121332964 @default.
• W2538625641 hasConcept C126322002 @default.
• W2538625641 hasConcept C156957248 @default.
• W2538625641 hasConcept C207103383 @default.
• W2538625641 hasConcept C2776301958 @default.
• W2538625641 hasConcept C2776704044 @default.
• W2538625641 hasConcept C2776839432 @default.
• W2538625641 hasConcept C2777628954 @default.
• W2538625641 hasConcept C2778661090 @default.
• W2538625641 hasConcept C2779161974 @default.
• W2538625641 hasConcept C44249647 @default.
• W2538625641 hasConcept C61511704 @default.
• W2538625641 hasConcept C71924100 @default.
• W2538625641 hasConcept C72563966 @default.
• W2538625641 hasConceptScore W2538625641C120665830 @default.
• W2538625641 hasConceptScore W2538625641C121332964 @default.
• W2538625641 hasConceptScore W2538625641C126322002 @default.
• W2538625641 hasConceptScore W2538625641C156957248 @default.
• W2538625641 hasConceptScore W2538625641C207103383 @default.
• W2538625641 hasConceptScore W2538625641C2776301958 @default.
• W2538625641 hasConceptScore W2538625641C2776704044 @default.
• W2538625641 hasConceptScore W2538625641C2776839432 @default.
• W2538625641 hasConceptScore W2538625641C2777628954 @default.
• W2538625641 hasConceptScore W2538625641C2778661090 @default.
• W2538625641 hasConceptScore W2538625641C2779161974 @default.
• W2538625641 hasConceptScore W2538625641C44249647 @default.
• W2538625641 hasConceptScore W2538625641C61511704 @default.
• W2538625641 hasConceptScore W2538625641C71924100 @default.
• W2538625641 hasConceptScore W2538625641C72563966 @default.
• W2538625641 hasLocation W25386256411 @default.
• W2538625641 hasOpenAccess W2538625641 @default.
• W2538625641 hasPrimaryLocation W25386256411 @default.
• W2538625641 hasRelatedWork W1483765694 @default.
• W2538625641 hasRelatedWork W2063989771 @default.
• W2538625641 hasRelatedWork W2097430541 @default.
• W2538625641 hasRelatedWork W2257941489 @default.
• W2538625641 hasRelatedWork W2341401458 @default.
• W2538625641 hasRelatedWork W2554752245 @default.
• W2538625641 hasRelatedWork W2589920306 @default.
• W2538625641 hasRelatedWork W2798072661 @default.
• W2538625641 hasRelatedWork W2805977590 @default.
• W2538625641 hasRelatedWork W2889022633 @default.
• W2538625641 hasRelatedWork W2907911263 @default.
• W2538625641 hasRelatedWork W2968823402 @default.
• W2538625641 hasRelatedWork W2979441343 @default.
• W2538625641 hasRelatedWork W2980533698 @default.
• W2538625641 hasRelatedWork W2980609426 @default.
• W2538625641 hasRelatedWork W2990384780 @default.
• W2538625641 hasRelatedWork W3037580416 @default.
• W2538625641 hasRelatedWork W3089244478 @default.
• W2538625641 hasRelatedWork W3186149284 @default.
• W2538625641 hasRelatedWork W3209289204 @default.
• W2538625641 isParatext "false" @default.
• W2538625641 isRetracted "false" @default.
• W2538625641 magId "2538625641" @default.
• W2538625641 workType "article" @default.